StreetAlpha.app
Home › Stocks › EQ

Equillium, Inc. (EQ)

Healthcare
$1.06
▼ −5.36%
LAST CLOSE · NOV 20

Equillium is a La Jolla biotechnology company developing treatments for autoimmune and inflammatory diseases, starting with ulcerative colitis. It last closed at $1.06 on Nov 20, down 5.36% on the day. The next earnings report for EQ is expected around Wed, Mar 24, 2027, after the close. For the quarter ended Sep 2026, EQ reported EPS of -$0.04. Over its last 8 reports the stock moved an average of 15.5% the session after earnings. Over the last 12 months EQ insiders bought $0 of stock on the open market and sold $2.4M, according to SEC Form 4 filings.

AI Auto Pilots
Is EQ in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold EQ.

Key Stats

Last 12 months
Results
Net income
−$18.4M
EPS (diluted)
−$0.12
Free cash flow
−$15.5M
Valuation
Market cap
$87.3M
82.3M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$53.3M
At Sep 30
Shareholder equity
$52.7M
Shares outstanding
82.3M
At Nov 10
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$39.1M−$39.1MFY2021FY2022: −$62.4M−$62.4MFY2022FY2023: −$13.3M−$13.3MFY2023FY2024: −$8.1M−$8.1MFY2024FY2025: −$22.4M−$22.4MFY2025

From EQ's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Next report
Mar 24
Estimated date · After the close
Reported EPS
-$0.04
Quarter ended Sep 2026
Year ago EPS
-$0.06
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.17Dec '24Mar 2025: -$0.24Mar '25Jun 2025: -$0.16Jun '25Sep 2025: -$0.06Sep '25Dec 2025: $0.02Dec '25Mar 2026: -$0.06Mar '26Jun 2026: -$0.04Jun '26Sep 2026: -$0.04Sep '26Latest -$0.04
Revenue by quarter
Not enough quarters on file yet.
How EQ moved after its last 8 reports
Average move the session after a report ±15.5%
Nov 12, 2026After the close−2.3%
Aug 13, 2026After the close+17.4%
May 13, 2026After the close+12.1%
Mar 25, 2026After the close0.0%
Nov 13, 2025After the close+23.8%
Aug 4, 2025Time not announced−20.7%
Mar 27, 2025Time not announced−35.6%
Nov 13, 2024After the close−12.3%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on EQStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on EQ
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on EQ

Technical Analysis

EQ · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 25% below its 20 day and 38% below its 50 day average. It is 96% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 33), near oversold. The nearest support is the Pivot S1 at $1.02, and the nearest resistance the Pivot at $1.09.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 11.8%/day
Key levels
$3.5452 week high+234.0%
$2.08200 day average+96.2%
$1.95100 day average+84.0%
$1.48Swing high (Oct 29)+39.6%
$1.4750 day average+38.7%
$1.3220 day average+24.5%
$1.14Pivot R1+7.5%
$1.09Pivot+2.8%
$1.06Last close
$1.02Pivot S1−3.8%
$0.8152 week low−23.6%
Indicators
RSI (14)33.40Weak, oversold below 30Neutral
MACD-0.10Below its signal lineBearish
Stochastic8.8Near the bottom of its rangeOversold
ADX (14)21.0Weak trend
Williams %R-95.7Oversold below −80, overbought above −20Oversold
CCI (20)-146.5Oversold below −100, overbought above 100Oversold
Rate of change−29.8%Change over 10 sessionsBearish
ATR (14)$0.13Typical daily range, 11.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for EQ

What happened before

See how EQ did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow EQ usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How EQ has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for EQHow many large options trades hit EQ, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

EQ Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲32 buying vs 27 selling
  • ▼Held by funds -0.9 pts
  • ▲Funds holding +6
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding6660+10.0%
In funds' top 10110.0%
Held by funds49.8%50.7%−0.9 pts
New / increased15 / 1718 / 17−8.6%
Reduced / sold out18 / 914 / 8+22.7%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See EQ institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

EQ Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$2.4M11 sales · 3 insiders
70% of the selling was under pre-arranged trading plans.
2025-12 sold $197K2026-01 sold $8K2026-02 sold $328K2026-03 sold $663K2026-05 sold $459K2026-06 sold $767KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Jun 5Stephen ConnellyPresident and CSOSale230,975$3.13$724K
Jun 5Christine ZedelmayerSr. Vice President and COOSale plan14,584$2.93$43K
May 28Christine ZedelmayerSr. Vice President and COOSale plan95,833$2.79$267K
May 28Penny TomPrincipal Accounting OfficerSale plan65,000$2.95$192K
Mar 13Christine ZedelmayerSr. Vice President and COOSale plan120,312$2.50$301K
Mar 9Christine ZedelmayerSr. Vice President and COOSale plan181,219$2.00$362K
Every insider buy and sale for EQ over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See EQ insider trades →

From SEC Form 4 filings by EQ's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether EQ is in one of them and how their past EQ trades turned out.

EQ in the AI portfolios
Loading…

EQ News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered EQ in an article yet. Here's the latest on the wider market.

EQ in the news

About Equillium

Equillium is a biotechnology company in La Jolla, California, that develops treatments for severe autoimmune and inflammatory diseases. Its lead candidate, EQ504, works on the aryl hydrocarbon receptor and is being developed first for ulcerative colitis and other gut diseases. The company also has an oral candidate, EQ302, that blocks two inflammatory signaling proteins and is aimed at celiac disease. Both candidates are still in development and not yet sold, with patients who have gut and immune disorders as the intended users.

Headquarters
La Jolla, CA